The University of Montpellier Secures New Funding Through Its NANOREMEDI Project
TThe Functional Nano-Scaffolds for Regenerative Medicine, also known as NANOREMEDI, led by Gilles Subra, a professor in the Faculty of Pharmacy, and Cécile Echalier, a faculty member specializing in chemistry of biomaterials at IBMM, with the participation of Danièle Noël’s team at IRMB, has secured, as part of the Marie Skłodowska-Curie Actions Doctoral Network, €565,000 in funding for the training and research of doctoral students at the University of Montpellier.
The NANOREMEDI Project in a Nutshell
NANOREMEDI, which officially launched on September1, 2022, for a duration of four years, is a Marie Skłodowska-Curie Actions Doctoral Network project led by a consortium of six universities in Europe. The main objective is to train 13 doctoral researchers in the field of peptides and nanomaterials. Each fellow will be jointly supervised by two universities and will spend the majority of their time at the university that recruits them, nine months at the second university, and three months at an industrial partner. In addition, these doctoral researchers will benefit from cross-cutting and interdisciplinary training and will participate in international workshops organized by the NANOREMEDI partners. The University of Montpellier will therefore recruit two students for this project in collaboration with the University of Milan (Italy) and IC Nanogune (San Sebastián, Spain), and will host two others for a period of 9 months each, also in collaboration with the University of Milan and the Hebrew University of Jerusalem.
From a scientific perspective, the project aims to improve human health by addressing three major challenges:
- The engineering of vascular grafts to replace damaged arteries,
- The development of stem cell-based biotherapies for bone and cartilage repair,
- The development of strategies to promote implant integration and prevent bacterial contamination.
Funding for the IBM and the IRMB at the University of Montpellier
Along with the University of Montpellier, five other universities: the University of Milan (Department of Pharmaceutical Sciences), the Universitat Politècnica de Catalunya (Barcelona Tech, Department of Chemical Engineering), the Hebrew University of Jerusalem (Institute of Chemistry), the University of Pavia (Department of Drug Sciences), IC NANOGUNE (“Self-Assembly” Group, San Sebastian), as well as 11 industrial partners, including two French companies (Lynxter and Genepep), are leading the NANOREMEDI project, which has received total funding of €3.4 million.
As part of this initiative, theUM has been awarded €565,000. This provides the IBMM and the IRMB with the resources to fund supplies and equipment to support doctoral research and organize workshops. This same funding from the Marie Skłodowska-Curie Actions Doctoral Network enables the implementation of doctoral programs in partnership with universities and companies from various sectors across Europe to train highly qualified doctoral students, stimulate their creativity, strengthen their capacity for innovation, and ensure their long-term employability in Europe.
Practical Information:
The NANOREMEDI Project in Detail: https://www.nanoremedi.eu/